ImageneBio Grants Inducement Awards to New Employees

SAN DIEGO, Oct. 02, 2026 /CourierPR/ -- ImageneBio, Inc., a clinical-stage biotechnology company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, has announced the granting of inducement awards to three newly hired non-executive employees. These awards, granted on September 30, 2026, are in line with Nasdaq Listing Rule 5635(c)(4) and consist of 90,775 restricted stock units (RSUs) and 32,725 non-qualified stock options (NSOs).

The RSUs and NSOs are subject to the terms and conditions of the Company’s 2025 Equity Inducement Plan. The RSUs for two of the employees will vest in equal annual installments over four years, while the RSUs granted to one employee will vest over four years with 25% vesting after one year and the balance vesting in 12 equal quarterly installments thereafter, contingent upon continuous service through each vesting date.

Each NSO has an exercise price equal to $4.58 per share, the closing price of Imagene’s common stock on the day of grant. The NSOs will vest over four years, with 25% of the shares vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months, subject to the grantee’s continuous service through each vesting date.

ImageneBio is dedicated to developing therapeutics with differentiated clinical profiles. The company’s program, olevaprubart, is a receptor targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis.

This strategic move by ImageneBio underscores its commitment to attracting and retaining top talent through equity incentives, aligning the interests of new hires with the long-term success of the company.